GlassScriptPhysician profile
Craig A Garfield
NPI 1174575849
$13,219.55
in general payments reported to CMS, 2019-2025
42 companies · $1,973 in 2025
The $1,973 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,447 · 2020: $1,361 · 2021: $2,125 · 2022: $2,171 · 2023: $2,066 · 2024: $2,076 · 2025: $1,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,095 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,095.07 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,865.64 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,495.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,482.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,306.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $859.10 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Abbvie INC. | $801.25 | 2021-2025 | |
| Pfizer INC. | $693.25 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $522.79 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $456.41 | 2019-2025 | Capvaxive, Vaxneuvance, Pneumovax 23 |
| Astellas Pharma US INC | $429.24 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $424.62 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $420.79 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $336.62 | 2019-2025 | Spravato |
| Xeris Pharmaceuticals, INC. | $319.09 | 2021-2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $263.28 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Garfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.